Atrial Fibrillation Market: By Treatment Type (Non – pharmacological, Pharmacological, Others) End User (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Laboratories, Others) and Geography  

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

The atrial fibrillation market is anticipated to be valued at USD 1,945.6 million in 2021 and is expanded to grow at a significant CAGR of 7.2% over 2022-2028. Atrial fibrillation is the most common problem with the heartbeat's rate or rhythm. Atrial fibrillation is caused by disordered signals that cause the two top chambers of the heart (the atria) to squeeze very quickly and out of sync. The increased prevalence of heart attacks and high blood pressure among people is driving the atrial fibrillation industry. Furthermore, the market is also boosted by the prevalence of obesity, diabetes, and metabolic syndrome. The market is predicted to develop due to the growing patient pool and the geriatric population suffering from lifestyle diseases like atherosclerosis and heart failure. The key players are manufacturing advanced catheter ablation for the treatment of atrial fibrillation and reducing the risk of stroke in patients, which has paved the way for lucrative opportunities in the industry. A favorable regulatory scenario would also propel growth in this market. Due to an increase in the adoption of cardiac monitoring systems during the treatment of atrial fibrillation, the surgical segment generated the most revenue in 2020. By end-user, the hospital segment registered the highest revenue in 2021, owning to the increased adoption of laser and radiofrequency methods for catheter ablation. An increase in number of patients with arrhythmia or an irregular heartbeat problem has resulted in a growth in demand for cardiac monitors. Recent Market Developments: In Feb 2022, Boston Scientific Corporation announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures. In Jan 2022, Medtronic plc, a global leader in healthcare technology, announced that it has entered into a definitive agreement to acquire Affera, Inc., a Boston area-based, privately held medical technology company. Affera designs and manufactures cardiac mapping and navigation systems and catheter-based cardiac ablation technologies, including a differentiated, focal pulsed field ablation solution, for the treatment of patients with cardiac arrhythmias (irregular heartbeats) such as atrial fibrillation (AF).

Global Atrial Fibrillation Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific
Atrial Fibrillation Market

Because of the rising patient pool and the geriatric population suffering from lifestyle diseases such as atherosclerosis and heart failure, the market is expected to rise. Furthermore, due to the rising prevalence of obesity, the number of persons suffering from atrial fibrillation is rising. As a result, it's thought that increasing obesity rates are adding to the market's expansion. Scarcity of experienced professionals and adverse preference for pharmacological treatments over atrial fibrillation devices are the main factors hampering the global atrial fibrillation market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Atrial Fibrillation Market Segmentation

Treatment Type
  • Non – pharmacological
  • Pharmacological
  • Others
End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Catheterization Laboratories
  • Others
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The atrial fibrillation market is projected to expand at a CAGR of 7.2% during the forecast period

AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Inc., Johnson and Johnson Ltd., Abbott Laboratories  

North American is the fastest-growing region for atrial fibrillation market

  • AtriCure, Inc.
  • Biosense Webster, Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Corporation
  • CardioFocus, Inc.
  • Endoscopic Technologies, Inc.
  • Sanofi Aventis, Inc.
  • Johnson and Johnson Ltd.
  • Abbott Laboratories